FDA clears Wegovy’s label to include heart health benefits

Novo Nordisk’s Wegovy has been given a first-in-class approval by the FDA to reduce the risk of serious cardiovascular conditions in people who are overweight or obese.

Advantage Novo Nordisk in battle of weight-loss drugs

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in

Low-cost polypill could dramatically cut heart attacks, stro...

AZ’s Forxiga gets heart claim data on its EU label

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...

Pfizer and Merck's diabetes contender looks to challenge Jar...

Merck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin